The abstract is read at the publisher; the summary is JClub's.
In 1,983 high-causality idiosyncratic DILI cases in the U.S. DILIN prospective registry (2004–2024), median peak bilirubin, INR, and severity scores fell over time while HDS and antineoplastic shares rose.
- Why it matters: Temporal shifts in suspected drug causes and clinical severity are important for interpreting changing DILI risk and for targeting prevention and monitoring strategies.
- What they did: Consecutive high-causality cases were followed for 6 months across multiple DILIN sites, then compared by time period and by suspect drug class, age, sex, and prior chronic liver disease status.
- The result: Antibiotic-attributed cases declined (including isoniazid and nitrofurantoin), while herbal and dietary supplement and antineoplastic (including checkpoint inhibitors) cases increased; CLD patients had higher mortality, pediatric cases had lower mortality than adults, and oncology DILI had 30% 6-month mortality mostly from non-liver causes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.